

## HR 2891

Preserve Access to Affordable Generics and Biosimilars Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 28, 2021

**Current Status:** Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.

**Latest Action:** Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13. (Sep 29, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/2891>

### Sponsor

**Name:** Rep. Nadler, Jerrold [D-NY-10]

**Party:** Democratic • **State:** NY • **Chamber:** House

### Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Buck, Ken [R-CO-4]	R · CO		Apr 28, 2021
Rep. Cicilline, David N. [D-RI-1]	D · RI		Apr 28, 2021
Rep. Maloney, Carolyn B. [D-NY-12]	D · NY		Apr 28, 2021
Rep. Owens, Burgess [R-UT-4]	R · UT		May 28, 2021
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jul 20, 2021
Rep. Budd, Ted [R-NC-13]	R · NC		Sep 24, 2021
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Sep 28, 2021

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 29, 2021
Judiciary Committee	House	Markup By	Sep 29, 2021

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 5237	Related bill	<b>Nov 1, 2022:</b> Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
117 HR 5260	Related bill	<b>Nov 1, 2022:</b> Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
117 S 1428	Related bill	<b>Dec 9, 2021:</b> Placed on Senate Legislative Calendar under General Orders. Calendar No. 180.

## **Preserve Access to Affordable Generics and Biosimilars Act**

This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar.

An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects.

When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations.

The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.

## **Actions Timeline**

---

- **Sep 29, 2021:** Committee Consideration and Mark-up Session Held.
- **Sep 29, 2021:** Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 28 - 13.
- **Apr 29, 2021:** Referred to the Subcommittee on Health.
- **Apr 28, 2021:** Introduced in House
- **Apr 28, 2021:** Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

# LegiList

CONGRESS, MADE CLEAR.

## Search Every Federal Bill, Law, and Vote

LegiList is the fastest way to research Congress. Track any bill from introduction to enactment, see how every legislator voted, follow committee activity, and read the full text of every bill — all in one place, always up to date.

[legilist.com](https://legilist.com)

## Free Course: Learn How Congress Actually Works

LegiList Learn is a free, self-paced course that walks through the entire legislative process — from drafting a bill to a presidential signature. Seven modules, plain language, no politics. Earn a certificate when you finish.

[legilist.com/learn](https://legilist.com/learn)

## Developer API: Build Apps on Legislative Data

The LegiList API gives developers direct access to bills, votes, legislators, committees, and more. Start free with 1,000 requests per day — no credit card required. Upgrade to Pro when you need to scale.

[legilist.com/api](https://legilist.com/api)

Public data belongs to the public. — [legilist.com](https://legilist.com)